AstraZeneca (AZN.L): Mixed lung cancer updates across the portfolio; eVOLVE-Lung02 discontinuation improves 2027 catalyst set up 17 August 2026 | 8:52AM BST Equity Research This morning, AZN announced: 1) positive topline results from the Phase 3 SAFFRON trial, where Tagrisso plus Orpathys (MET inhibitor) showed positive PFS and OS results in 2L EGFR+ MET+ NSCLC; 2) discontinuation of the Phase 3 eVOLVE-Lung02 trial testing volrustomig (PD-1xCTLA-4) + chemo vs. Keytruda + chemo in PD-L1 low (<50%) NSCLC at ...

C A Z E N O V E Europe Equity Research 17 August 2026 AstraZeneca Clinically meaningful SAFFRON data for Tagrisso and Orpathys, and Enhertu DL04 success partially offset by discontinuation of eVOLVE-Lung02 for volrustomig This morning, Astra announced the results from three read-outs; (i) the SAFFRON trial for Tagrisso + Orpathys in 2L+ EGFRm NSCLC, which showed a statistically significant and clinically meaningful benefit on PFS and OS; (ii) the Destiny- Lung04 results for Enhertu, which showed a statistic ...

核心观点 - 独立数据监测委员会建议终止volrustomig联合化疗的临床试验，因其不太可能达到主要终点[1] 临床试验终止 - 独立数据监测委员会基于对试验数据的评估，做出终止建议[1] - 终止原因为volrustomig联合化疗方案达到主要终点的可能性较低[1]

核心观点 - 阿斯利康宣布终止一项针对转移性非小细胞肺癌患者的后期阶段试验，该试验测试了volrustomig联合化疗方案[1] 试验终止 - 阿斯利康于周一宣布终止一项后期阶段试验[1] - 该试验评估了volrustomig联合化疗在转移性非小细胞肺癌患者中的疗效[1]